ISSN No:-2456-2165

Nanosizing – Oral Formulation Development

Shubham Yadav*; Dr. Swarup J. Chatterjee
S.N. College of Pharmacy Jaunpur (U.P.) 222132

Abstract:- One of the main issues in drug development is poor water solubility, which prevents most medications from achieving sufficient oral bioavailability. The decrease of an API's size to the sub-micron level is known as nanosizing, and the final particle size typically falls between 100 and 200 nm. The API's rate of dissolution is significantly increased by the reduction in particle size, which ultimately results in a large increase in bioavailability. The principles guiding nanosizing, the creation and characterisation of nanoformulations, and the current state of use of such formulations are all intended to be highlighted in this paper.

Keywords:- *Particle Size, Nanosizing Technique, Solubility, Absorption and Bioavailability.*

I. INTRODUCTION

The number of drug candidates under development has continuously expanded due to recent advances in combinatorial chemistry, biology, and genetics. Because cell membranes are phospholipidic, medicinal compounds frequently need to be somewhat lipophilic in order to exert their pharmacological action on the target tissue as well as to guarantee absorption through the intestinal wall following oral administration. High lipophilicity naturally results in low water solubility, even though it is beneficial for compound permeability. As the initial stage of oral absorption involves the drug ingredient dissolving in the contents of the gastrointestinal lumen, low water solubility is quickly emerging as the main challenge for formulation scientists working on oral drug delivery of drug compound.

The process of reducing the active medicinal ingredient's particle size to less than a micron is known as nanosizing. Although the pharmaceutical industry has long used particle size reduction, improvements in milling technology and our comprehension of these colloidal systems have made it feasible to produce API particles with a reproducible size range of 100–200 nm. Surfectants or polymers are frequently used as stabilizers for the sub-micron particles in nanosuspension. The resulting nanosuspension can be further processed to create a conventional dosage form, like pills, which can be taken orally. In order to increase the bioavailability of poorly soluble compounds, BCS Class II, and IV, these nanoformulations offer faster rates of dissolution for drug compounds and cooperate with other technologies, such as surfactants, liquid-filled capsules, or solid dispersions of drugs in their amorphous state. It is estimated that at least 40% of the active compounds identified by combinatorial screening processes are poorly soluble in water. When such compounds are made using traditional methods, the therapeutic action in preclinical screening is often variable and heavily influenced by the formulation.

ISSN No:-2456-2165



Fig 1.Graphical Abstract of Nanosizing

Problems like inadequate and extremely variable bioavailability in the clinic from traditional formulation are frequently associated with poorly water soluble medicines. The dosage forms are frequently affected by the patient's fed fasted state, and the beginning of effect is typically slower than anticipated. All of them have led to poor performance and less-than-ideal dosage. In vitro, through dissolution testing, and in vivo invasively through preclinical research and human clinical trials, the advantages of nanoformulation for oral drug delivery have been demonstrated. In addition to improving bioavailability, decreasing variability, and greatly increasing the rate of dissolution in vitro, nano scale crystalline API also counteracts the desired favorable food impact that comes with oral drug molecules. Five pharmaceutical products currently use Nano crystalline API to accomplish their drug-related objectives.

The theoretical under pinning and practical considerations of using nanosizing to improve the oral bioavailability of pharmaceutical substances will be attempted to be covered in this review. The development of a man-sized formulation through several drug development phases is covered in this work, including formulation element including selection and bio performance evaluation. When applicable, examples of how nanosizing can be used to enhance oral absorption or contrasted with other cut edge oral delivery methods. Review of the literature theoretical issues of increasing the rate of disintegration through nanosization the Nernst Whitney equation states that a solid API's rate of dissolution is proportional to surface area exposed during the dissolving.

II. LITERATURE SURVEY

A. Nanoformulation Development

Formulating a nanoformulation is one of the more complicated formulation tasks as compared to formulation work utilizing traditional processes like wet granulation (WG), roller compaction (RC) or direct compression (DC). To preserve the nature and characteristics of nanoparticles, the drug particle must be stabilized and meticulously formed in addition to being converted into nanosized domains by technically challenging procedures.

B. Biopharmaceutical Evaluation of Nano Formulations

Given the intricacy of nano suspension production, prompt evaluation of gain invivo exposure particularly crucial during the penicillin phase. Invitro experiment and computational method may aid in the initial phase of bio pharmaceutical assessment of nanosuspension. Promising formulations from this test can then be evaluated invivo, initial in preclinical animal and then in clinical trials. Although the application of nanosizing to oral drug delivery of immediate release formulations the main focus of this research, nanoformulations have lately begun to garner attention as potential technology for alternate routes of administration. The overview that follows offers some comparatively scant information in this area. Scholar et al. employed atovaquone nanosuspensions in a mouse model of toxoplasma encephalitis in order to overcome inadequate oral absorption by such an intravenous method of administration.

C. Future Direction

Although nanoformulations present an alluring option for compounds that are not very water soluble, not all drug development candidates will benefit from the compound-dependent impact of nanosizing on in vivo performance. Early in the development process, a thorough evaluation of the compound's medicinal qualities can help determine whether alternate technologies, like solid dispersion or liquid-filled capsules, should be taken into consideration.

Particles that are nanocrystalline an electron micrograph and a diagrammatic representation of drug particles prepared as a colloidal dispersion are examples of nanocrystalline particles, which are nanometer-sized drug particles of a poorly water-soluble chemical. The morphology of the unprocessed crystalline powder, the crystals' fracture plane, and the interactions between the drug and stabilizer all influence the geometrical shape of the electron-dense nanometer-sized particles.

D. Application for Oral Delivery

Dissolution kinetics is a key factor in the enhanced pharmacokinetic characteristics of nanoparticle formulations of weakly water-soluble drugs. Any drug's intrinsic solubility and particle size both affect its release rate. When a medicine is weakly soluble in water, the dissolution is controlled by the surface area of the drug's particles. The Nernst-Brunner and Levich variant of the Noyes-Whitney model of dissolution explains this.

Injectable product applications for injectable medications that are not very soluble in water, nanocrystalline formulations make an ideal dosage form (Merisko-Liversidge et al., 1996, Cooper, 2000, Bittner & Mount field, 2002).



Fig 2: Various Advantages of Nanosizing

In general, a variety of well-established performance problems are linked to chemicals that are poorly soluble in water. By increasing surface area, particle size reduction is intended to improve the pace at which a weakly water soluble molecule dissolves. Performance can be significantly improved by increasing the surface area. Dissolution, absorption, and target engagement are necessary for an agent to be absorbed and/or interact with a biological target. Wet media applications pulverized nanomaterials the capacity to construct poorly water-soluble compounds as drug particles with a Nano scale size has a major effect on performance. Benefits fall into three main categories: dose escalation for increased efficacy, safety and patient compliance, and performance improvements pertaining to dissolving properties. The goods listed below are derived from a wet media milling approach.

E. The Unmet Need

In the late 1980s and early 1990s, the pharmaceutical industry made substantial use of combinatorial chemistry to identify targets and generate lead candidates. It was widely believed that there was a bright future for creating compounds with high affinity binding constants for their biological targets and appropriate physical/chemical properties that would make them suitable for use in pharmaceuticals, especially since there were vast chemical libraries available for new chemical entities.

F. Stability and Surface Modifiers/Stabilizers

The surface energy involved in the formation of nanoparticles from drug particles bigger than a few microns is a crucial aspect of particle size reduction. A positive free energy is produced by increasing the surface area. These nanoparticles have a tendency to aggregate and agglomerate into a less energy form if the surface is not dampened or sensitized. Derjaguin and Landau first characterized the classical dynamics of particle-particle interaction in the 1940s, and Verwey later improved upon it. As previously stated, nanosuspensions can be made as a stable liquid dispersion in a stabilizer solution that is based on water. However, the capacity to produce a solid dosage form—such as a capsule, tablet, or quick melt—usually results in a dosage form that the patient finds even more acceptable for oral indications. Having a lyophilized dosage form that is easily reconstituted before administration is frequently beneficial for injectables. Wet milling produced nanosuspensions.

III. PROCEDURE

A. Methods and Pathways for Creating Nanosuspensions

Nanosuspension can be produced using one of two reverse processing methods: "bottom-up" or "top-down." Both methods can be applied separately. While top down methods, such as media milling, may be a breakdown process from huge particles, bottom up approaches include precipitation, micro emulsification, and melt emulsification Fig. Benefits of high-pressure homogenization methods for nanoparticles (Nano crystals), high-pressure homogenization methods for no aqueous media (Nano pure), high-pressure homogenization methods for precipitation and high-pressure homogenization (Nano edge), and nanoparticles (Nano crystals).

B. Bottom-up Methods

Bottom-up Methods These methods create nanosized drug particles by allowing drug molecules to aggregate in the appropriate carrier. Medications must be dissolved in organic solvents before being combined with no solvents, typically water, in bottom-up technology. This causes the medications to precipitate and can be managed through a homogenization procedure. Small particles are best obtained via rapid precipitation, which is achieved by adding an anti-solvent to the drug solution and then homogenizing it at high speed. Under the right temperature circumstances, this method of crystal development occurs after nuclei form, and drug ingredients precipitate in an amorphous form from a supersaturated drug solution.

This process is highly easy, economical, and gives the product a high saturation solubility. Nonetheless, there are benefits to pharmacological nanosuspensions. Drug ingredients need to dissolve in at least one type of solvent, whether it be aqueous or non-aqueous. Another issue with this method is the solvent residue that remains in the finished product.



Fig 3 Schematic Diagram of the Nanosizing Process using Milling Technology

The same method described above was used to create a griseofulvin nanosuspension, with lecithin sodium taurodeoxicholate serving as the emulsifier and butyl acetate as the internal phase. Melt emulsification technique Another method for creating formulations at the nanoscale is the melt emulsification method. Kocbek and colleagues (2006) created the first ibuprofen nanosuspension using Using this method, ibuprofen was dissolved or dispersed in double-distilled water that had been heated over the drug's melting point. To create a fine drug dispersion, the solution was then homogenized at high speed using a high-speed homogenizer at the same temperature.

C. The Wet Media Milling Method

It has been demonstrated that for poorly water-soluble chemicals, wet media milling in a water-based fluid phase produces physically stable nanometer-sized particles. The method is basically a variation of production-scale, commercially accessible media mills, which are widely used in the paint, photography, and magnetic industries. Few drug delivery platforms that originated from small-scale bench-top experiments can claim to have been downscaled and sterilized onto equipment used by the pharmaceutical industry.

IV. SUMMARY

In summary, some drug particles are extremely hard, requiring several cycles of size reduction to reduce their size. A novel method for improving the solubility, bioavailability, and therapeutic efficacy of poorly soluble medications is the nanosizing of pharmacological formulations. This method increases the surface area of pharmaceuticals by reducing their particle size to the nanoscale scale, which improves their ability to interact with biological systems. The three main methods of nanosizing—precipitation, solvent evaporation, and milling—are each unique to the various medications. Nanosized preparations are versatile for a range of therapeutic applications since they can be delivered orally, intravenously, or transdermally. More significantly, formulations that are nanosized can offer better treatment results, less side effects, and targeted distribution. However, the majority of nanosized medication formulations face significant development problems related to stability, scalability, and regulatory approval. All things considered, nanosizing is a promising approach to pharmaceutical formulation that provides creative answers to persistent problems with therapeutic efficacy and distribution.

V. CONCLUSION

A workable solution to the majority of the challenges currently associated with the development and marketing of poorly water-soluble molecules is the use of wet milling technology in the synthesis of these compounds. Since the solubility characteristics of the medication have played a major role in the development of successful nanocrystal technology applied to a chemical entity, it is simple to adapt to any class of drug compounds. Drying and post-processing nanocrystalline formulations can result in pharmaceutical companies and regulatory bodies have generally accepted the idea of nanosizing poorly soluble medications to increase their bioavailability. However, only a small number of drug nanocrystal formulations have been made commercially available thus far. A number of recent advancements in nanosizing technology may indicate that this is becoming more common. Top-down methods' drawbacks, like protracted milling periods and abrasion problems, have been resolved. The following are issues with bottom-up techniques.

REFERENCES

[1]. Kumar, A., & Sharma, R. (2022). Nanotechnology in Drug Delivery: Principles and Practice. 2nd ed. Elsevier. pp. 45-60.
[2]. Zhang, L., & Chen, H. (2021. "Advances in Nanosizing Techniques for Oral Formulations." Journal of Pharmaceutical Sciences, 110(3), 1150-1165. https://doi.org/10.1016/j.jphs.2021.01.012
[3]. Patel, V., & Desai, K. (2020). Pharmaceutical Nanotechnology: A Comprehensive Approach. Springer. pp. 75-90.
[4]. Gupta, S., & Roy, P. (2019). "Stability Studies of Nanosized Drug Formulations." International Journal of Nanomedicine, 14, 1234-1245. https://doi.org/10.2147/IJN.S200012
[5]. Lee, J., & Park, Y. (2018). Nanocarriers for Drug Delivery: Applications and Innovations. Wiley. pp. 30-50.
[6]. Kumar, A., & Sharma, R. (2022). Nanotechnology in Drug Delivery: Principles and Practice. 2nd ed. Elsevier. pp. 45-60.
[7]. Zhang, L., & Chen, H. (2021. "Advances in Nanosizing Techniques for Oral Formulations." Journal of Pharmaceutical Sciences, 110(3), 1150-1165. https://doi.org/10.1016/j.jphs.2021.01.012
[8]. Patel, V., & Desai, K. (2020). Pharmaceutical Nanotechnology: A Comprehensive Approach. Springer. pp. 75-90.
[9]. Gupta, S., & Roy, P. (2019). "Stability Studies of Nanosized Drug Formulations." International Journal of Nanomedicine, 14, 1234-1245. https://doi.org/10.2147/IJN.S200012
[10]. Lee, J., & Park, Y. (2018). Nanocarriers for Drug Delivery: Applications and Innovations. Wiley. pp. 30-50.
[11]. Singh, R., & Verma, A. (2021). "Nanocrystals for Solubility Enhancement: A Review." European Journal of Pharmaceutics and Biopharmaceutics, 152, 23-34. https://doi.org/10.1016/j.ejpb.2020.11.005.
[12]. Thomas, M., & Patel, R. (2020). Innovative Drug Delivery Systems: Nanotechnology Applications. CRC Press. pp. 105-120.
[13]. Chen, S., & Yang, Y. (2022). "Regulatory Challenges in Nanotechnology." Regulatory Affairs Journal, 10(1), 14-29. https://doi.org/10.1016/j.raj.2022.03.002.
[14]. Kim, H., & Choi, J. (2019). "Bioavailability Enhancement of Poorly Soluble Drugs." Molecular Pharmaceutics, 16(4), 1452-1465. https://doi.org/10.1021/acs.molpharmaceut.8b00912
[15]. Reddy, L., & Suresh, R. (2021). Pharmaceutical Nanotechnology: From Laboratory to Market. Academic Press. pp. 200-215.
[16]. Wang, Y., & Zhao, X. (2020). "Nanosizing Techniques for Drug Delivery: A Review." Asian Journal of Pharmaceutical Sciences, 15(3), 321-335. https://doi.org/10.1016/j.ajps.2019.12.002.
[17]. Smith, J., & Johnson, L. (2021). Nanomedicine: Principles and Applications. 3rd ed. Taylor & Francis. pp. 89-105.
[18]. Turner, M., & Brown, T. (2019). "Characterization of Nanoparticles in Drug Formulations." Journal of Nanoscience and Nanotechnology, 19(2), 675-692. https://doi.org/10.1166/jnn.2019.16489
[19]. O'Reilly, T., & Hutton, S. (2022). Formulation Development for Nanoparticles: Techniques and Strategies. Elsevier. pp. 150-165.
[20]. Lee, S., & Kim, J. (2021). "The Role of Surfactants in Nanosizing." Colloids and Surfaces B: Biointerfaces, 197, 111457. https://doi.org/10.1016/j.colsurfb.2020.111457
[21]. Davis, K., & Roberts, C. (2020). Advanced Drug Delivery Systems. Academic Press. pp. 60-75.
[22]. Jones, M., & Patel, N. (2019). "Nanocrystals as a Drug Delivery System: Challenges and Opportunities." Pharmaceutical Research, 36(5), https://doi.org/10.1007/s11095-019-2666-4.
[23]. Martin, A., & Thomas, G. (2022). "Oral Bioavailability of Nanosized Formulations." Drug Delivery and Translational Research, 12(3), 1234-1246. https://doi.org/10.1007/s13346-021-00934-7.
[24]. Harrison, L., & Wu, Z. (2021). Nanotechnology for Drug Delivery: Current Perspectives. Wiley. pp. 112-130.
[25]. Gupta, A., & Mehta, A. (2020). "Nanosizing for Enhanced Drug Solubility." International Journal of Pharmaceutics, 586, 119510. https://doi.org/10.1016/j.ijpharm.2020.119510.

[26]. Taylor, E., & White, C. (2019). "Polymeric Nanoparticles for Oral Delivery." Current Drug Delivery, 16(1), 67-78.
[27]. https://doi.org/10.2174/
[28]. Singh, P., & Kaur, G. (2021). Nanotechnology in Pharmaceutical Sciences. 1st ed. Springer. pp. 45-60.
[29]. Verma, S., & Singh, J. (2020). "Stability of Nanoparticles: A Review." Journal of Nanobiotechnology, 18(1), 15.
[30]. https://doi.org/10.1186/s12951-020-05660-3.
[31]. Kim, S., & Park, H. (2021). "Oral Nanoparticle Delivery Systems: Recent Advances." Molecular Pharmaceutics, 18(6), 2345-2358. https://doi.org/10.1021/acs.molpharmaceut.1c00123.
[32]. Bell, T., & Wong, K. (2022). Drug Development and Delivery: Nanotechnology Applications. Elsevier. pp. 201-215.
[33]. Chen, L., & Yu, J. (2020). "Challenges in the Development of Nanosized Formulations." European Journal of Pharmaceutical Sciences, 144, 105189. https://doi.org/10.1016/j.ejps.2019.105189.
[34]. Patel, S., & Jha, A. (2019). "Comparative Study of Nanosized versus Conventional Formulations." Journal of Drug Targeting, 27(8), 912-922. https://doi.org/10.1080/1061186X.2019.1581860.
[35]. Raghavan, K., & Patel, R. (2021). "Nanoparticle Applications in Cancer Therapy." Cancer Nanotechnology, 23(2), 101-115.
[36]. https://doi.org/10.1089/cnr.2021.0080.
[37]. Zhang, Y., & Sun, W. (2020). Nanotechnology in Oral Drug Delivery. 1st ed. Academic Press. pp. 150-170.
[38]. Mohan, M., & Gupta, R. (2022). "Nanocarriers for Targeted Drug Delivery." International Journal of Nanomedicine, 17, 543-559. https://doi.org/10.2147/IJN.S310001.
[39]. Rao, S., & Singh, P. (2019). "Nanosizing Techniques: A Review." Current Drug Delivery, 16(6), 485-494.
[40]. https://doi.org/10.2174/1567201815666181122153405.
[41]. Verma, S., & Jain, N. (2021). "Polymeric Nanoparticles for Drug Delivery: Recent Trends." European Journal of Pharmaceutics and Biopharmaceutics, 157, 143-159. https://doi.org/10.1016/j.ejpb.2020.10.015.
[42]. Kumar, P., & Sharma, M. (2020). "Nanosizing Techniques in Drug Formulation." Journal of Pharmaceutical Sciences, 109(10), 2780-2790. https://doi.org/10.1016/j.xphs.2020.05.027.